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The fusion tyrosine kinase Bcr-Abl plays a fundamental role in the pathogenesis of chronic myeloid leukemia (CML).
Imatinib, a potent inhibitor of Bcr-Abl, has shown impressive clinical activity in CML patients. However, primary and acquired
resistance occurs in many patients and is associated with reactivation of Bcr-Abl in primary leukemia cells. Studies report-
ed over the past year have begun to elucidate the molecular basis of imatinib resistance, which may involve amplification of
BCR-ABL or, more commonly, mutations that introduce amino acid substitutions into the Bcr-Abl kinase. Biochemical analy-
sis and molecular modeling indicate that these mutant proteins retain kinase activity but are less sensitive to inhibition due
to structural changes that perturb drug binding. These studies establish a paradigm for elucidating resistance to targeted
therapeutics.
Forty years ago, the Philadelphia chromosome was identified
in hematopoietic cells from patients with chronic myeloid
leukemia (CML). This discovery heralded an extraordinary
series of experiments that have illuminated many fundamental
principles of cancer biology (reviewed in Sawyers, 1999). The
basic facts are now ingrained in the canon of modern medicine.
The Philadelphia chromosome results from a reciprocal
translocation that joins the BCR gene on chromosome 22 with
the ABL gene on chromosome 9. This fusion gene encodes
Bcr-Abl, a chimeric protein with aberrant tyrosine kinase activi-
ty. The clinical course of CML is characterized initially by over-
production of differentiated
myeloid lineage cells (chronic
phase) and can be controlled for
months to years by treatment
with antiproliferative agents
such as hydroxyurea. Despite
normalization of peripheral
blood counts, the bone marrow
cells of CML patients treated in
this manner invariably retain 
the Philadelphia chromosome.
Chronic-phase CML ultimately
evolves to blast crisis, with
expansion of immature ele-
ments (blasts), effacement of
normal hematopoiesis, and
rapid demise. Blast crisis CML
is almost invariably refractory
to conventional chemotherapy;
the few remissions that occur
are short-lived. In addition to
being present in >95% of
patients with CML, BCR-ABL
fusions are found in ?25% of
adults and in 2%–5% of 
children with lymphoblastic leu-
kemia (ALL). Importantly, BCR-
ABL portends a poor clinical
prognosis in both CML and
ALL, with hematopoieitic stem cell transplantation (HSCT) rep-
resenting the only known curative treatment. Unfortunately,
HSCT requires an HLA-matched donor and is frequently asso-
ciated with substantial acute and chronic toxicities, particularly
in older individuals.
A major milestone in CML research was the recent devel-
opment of imatinib, a small molecule inhibitor of the Bcr-Abl
kinase that has been renamed a number of times (it is also
known as CGP 571148B, STI-571, and Gleevec) (reviewed in
Druker, 2002). Imatinib demonstrated remarkable activity in an
elegant series of trials performed by Brian Druker, Charles
Sawyers, and their colleagues that carefully assessed in vivo
pharmacodynamic endpoints in primary target cells and corre-
lated these data with clinical responses. In a landmark paper
that appeared last year, the
Sawyers group opened yet
another new chapter when
they identified BCR-ABL point
mutations in CML patients that
conferred resistance to ima-
tinib and reactivated the kinase
(Gorre et al., 2001). In this
issue of Cancer Cell, Shah and
associates (Shah et al., 2002)
describe a comprehensive mo-
lecular analysis of a larger
series of cases in which they
conclusively establish the pres-
ence of imatinib-resistant Bcr-
Abl species in a high proportion
of resistant and relapsed CML
patients, and they make a num-
ber of new insights. These find-
ings raise general questions
regarding the nature of cancer
genomes and how the inherited
and somatic mutations that
underlie the malignant pheno-
type modulate both the primary
response to targeted therapeu-
tics and the subsequent devel-
opment of resistance.
Two general types of molec-
ular responses can be distinguished in CML patients who are
treated with imatinib (Figure 1). In the first, there is both normal-
ization of the peripheral blood counts and disappearance of the
Figure 1. Patterns of imatinib resistance in CML
Patients treated with imatinib either clear the Philadelphia chromosome
from the bone marrow (complete cytogenetic response) or demonstrate
primary molecular resistance to the drug. Many patients with molecular
resistance have a sustained hematologic response and benefit from con-
tinuing treatment. Among patients with cytogenetic responses, some will
acquire resistance to imatinib and will relapse with reemergence of the
Philadelphia chromosome in the bone marrow.
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Philadelphia chromosome from unstimulated bone marrow cells
(major cytogenetic response). This occurs in a majority of
chronic-phase patients that receive imatinib as a single agent
(Kantarjian et al., 2002). It is not known what proportion of
patients that achieve a complete cytogenetic response will ulti-
mately relapse with reemergence of the Philadelphia chromo-
some. The second type of response is hematologic; that is,
patients show normalization of their blood counts but a signifi-
cant percentage of the bone marrow cells retain the
Philadelphia chromosome. Although these individuals certainly
benefit clinically from imatinib, they demonstrate primary resis-
tance at the molecular level because treatment does not fully
suppress the mutant clone and permit regrowth of normal
hematopoietic elements.
With this background in mind, how does the study of Shah
et al. advance the field, and what new questions do these stud-
ies raise? The authors focused on two cohorts of CML
patients—the first included patients who relapsed after a hema-
tologic response, while the second was comprised of chronic-
phase patients with sustained hematologic responses but pri-
mary molecular resistance (i.e., lack of a durable cytogenetic
response).The first group demonstrated substantial clinical het-
erogeneity at the time they were treated (16 myeloid blast
crises, 5 lymphoid blast crises, and 11 with chronic disease).
The first major finding was the high overall incidence of BCR-
ABL mutations (?90%) that was similar in patients who were
treated in chronic phase and blast crisis. There was a brief con-
troversy last year when some laboratories initially failed to
detect BCR-ABL mutations in CML patients that had been treat-
ed with imatinib (Hochhaus et al., 2001). Subsequent studies
confirmed the observations of the Sawyers group, and the new
work definitively establishes somatic BCR-ABL point mutations
as pervasive in CML. The very high frequency of mutations
identified by Shah et al. can be attributed to their decision to
clone and sequence multiple independent cDNA clones from
each case in order to identify mutant transcripts that comprised
a minority of the BCR-ABL transcripts in a given sample. The
authors make a further point is this regard, which is relevant to
the issue of primary versus acquired imatinib resistance, when
they note that mutant transcripts are especially likely to be in the
minority in patients who experience a hematologic, but not a
cytogenetic, response. This, in turn, infers that clones in these
individuals that express “wild-type” BCR-ABL are intrinsically
resistant to imatinib by alternative mechanisms because they
are not selected against by drug treatment.
What might these mechanisms be? Rapid drug efflux from
hematopoietic cells and inactivation of imatinib by binding to
serum α 1 acid glycoprotein have been proposed (Gambacorti-
Passerini et al., 2000; Mahon et al., 2000), but supporting in vivo
data are lacking (Jorgensen et al., 2002). Are there other sce-
narios under which CML clones that express wild-type BCR-
ABL and are exposed to therapeutic levels of the drug might
nevertheless demonstrate primary resistance? An obvious idea
is that BCR-ABL is not required to maintain the proliferative
advantage of some CML cells. However, there is no direct evi-
dence in support of this proposal, and a formidable body of
experimental data argues against it. First, introducing BCR-ABL
into mouse bone marrow causes leukemia (Daley et al., 1990;
Elefanty et al., 1990; Kelliher et al., 1990), and recent experi-
ments using a tetracyclene-regulated allele have shown that
BCR-ABL expression is tightly correlated with the leukemic phe-
notype in vivo (Huettner et al., 2000). Second, studies in anoth-
er mouse model support the general idea that oncogenes that
initiate lymphoma are required for tumor maintenance (Felsher
and Bishop, 1999). Finally, reactivation of the Bcr-Abl kinase as
a consequence of somatic BCR-ABL mutations that confer
resistance to imatinib in CML patients who relapse argues
strongly for an essential role of the fusion protein in maintaining
the disease.
The paper of Shah et al. extends our knowledge consider-
ably in this area. A compelling aspect of this work is the elegant
molecular modeling of the BCR-ABL mutations detected in CML
samples performed by John Kuriyan and his colleagues that is
based on the crystal structure of the c-Abl protein. One cluster
of mutations detected in CML patient samples changed each of
the invariant “X” positions in the Gly-X-Gly-X-X-Gly-X-Val
sequence of P loop, which contains a number of contact points
for binding ATP. These substitutions are likely to disrupt the dis-
torted conformation that the P loop adopts to permit binding of
imatinib. Another group of mutations change amino acids in Bcr-
Abl that contact imatinib and are thought to alter its interaction
with the drug independent of ATP binding. Shah et al. assessed
the functional significance of individual BCR-ABL mutations by
transfecting Ba/F3 cells. As expected, these mutant alleles
retained kinase activity and transforming potential and demon-
strated variable resistance to imatinib. Therapeutic doses of
imatinib efficiently inhibit the c-Kit kinase, which regulates the
growth and differentiation of discrete populations of hematopoi-
etic cells. The authors sequenced the kinase domain of c-Kit in
five patients with BCR-ABL mutations, but found no mutations.
Together, these studies provide strong support for the idea that
imatinib-resistant BCR-ABL mutations represent nonrandom
genetic lesions that are selected for in vivo because they confer
a proliferative advantage. This hypothesis predicts that clones
that express mutant BCR-ABL transcripts would dominate in the
clinical setting in which imatinib resistance develops in those
patients that initially achieved complete cytogenetic responses.
This data of Shah et al. are not definitive on this point because
only five of their patients experienced major cytogenetic
responses; however, relapse samples from a number of these
cases demonstrated 100% mutant transcripts.
If BCR-ABL is required to maintain the proliferative advan-
tage of CML cells in vivo, what might account for primary drug
resistance in clones that do not express mutant kinases?
Inasmuch as a substantial proportion of chronic-phase CML
patients treated with imatinib do not achieve complete cytoge-
netic responses, this question is of fundamental biologic and
clinical importance. One such mechanism—genomic amplifica-
tion of BCR-ABL—has been described in imatinib-treated
patients (Gorre et al., 2001). A logical starting point for investi-
gations of primary imatinib resistance involves assessing bone
marrow cells for evidence of Bcr-Abl kinase activity (this is usu-
ally done by measuring the phosphorylation levels of target mol-
ecules such as c-Cbl and Dok). If the Bcr-Abl kinase is active, it
is possible that the drug either is not reaching its intracellular
target or does not accumulate because of rapid exclusion from
target cells, or there is intrinsic resistance within certain
hematopoietic compartment or during certain stages of the cell
cycle. Each of these potential mechanisms merits investigation.
One important issue involves defining the relevant population(s)
of cells to focus on. Chronic-phase CML is a disease that origi-
nates in hematopoietic stem cells, which produce differentiated
progeny that populate the lymphoid, myeloid, erythroid, and
megakaryocytic lineages. Studies of leukemia-initiating cells in
CANCER CELL : AUGUST 2002 101
M I N I R E V I E W
NOD/SCID mouse models support the idea that malignant
hematopoiesis involves cells at multiple stages of maturation
and that leukemia-initiating stem cells comprise a small fraction
of the bone marrow (Bonnet and Dick, 1997). Similarly, cells that
are capable of initiating and maintaining CML are likely to repre-
sent <0.1% of bone marrow mononuclear cells. From the per-
spective of understanding imatinib resistance, studying their
vastly more numerous differentiated progeny may or may not be
relevant to the behavior of CML-initiating cells. Ascertaining the
percentage of early hematopoietic precursors that show BCR-
ABL expression in different CML patients, and the sensitivity of
cells at various levels of differentiation to imatinib, may uncover
novel mechanisms of resistance and might identify patients that
are likely to enter cytogenetic remission after treatment.
Expression microarray analysis of pediatric ALL samples corre-
lated discrete molecular signatures with specific chromosomal
translocations and identified expression patterns that predicted
a higher rate of relapse in some of these groups (Ferrando et
al., 2002; Yeoh et al., 2002). These data suggest that stem cell
populations that initiate leukemic growth specify distinct molec-
ular programs that can be distinguished in their progeny.
Similarly, prospective expression profiling of chronic-phase
CML bone marrow cells (or of subpopulations enriched for
leukemia-initiating cells) might identify pathways that modulate
responsiveness to imatinib.
The data of Shah et al. also raise general questions regard-
ing the role of genetic instability in tumorigenesis and in the
development of resistance to targeted therapeutics. By defini-
tion, chronic-phase CML is a genetically unstable disorder,
since patients invariably progress to blast crisis over time. Blast
crisis cells frequently demonstrate secondary cytogenetic
abnormalities, including acquisition of a second Philadelphia
chromosome.While the degree of genetic instability is difficult to
quantify in different cancers, it is perhaps useful to compare
what prevails in CML with some other malignancies. In particu-
lar, certain inherited cancer predispositions such as hereditary
nonpolyposis colon cancer, Fanconi anemia, and Bloom syn-
drome are associated with somatic mutation rates that are
increased thousands of times. Many epithelial cancers and ther-
apy-induced leukemias show widespread chromosomal aberra-
tions that have been termed “genomic chaos” by some com-
mentators. By contrast, chronic-phase CML and many other de
novo hematopoietic malignancies demonstrate chromosomal
translocations without other numerical or structural aberrations.
This has given rise to the notion that these cancers have rela-
tively stable genomes. The data of Shah et al. provide some
support for this idea in that they did not detect mutations in the
c-Kit kinase domain or in a 700 bp segment of BCR-ABL imme-
diately upstream of the kinase domain. Rather, the genetic
instability in CML cells is distinctly nonrandom and is intimately
related to achieving a growth advantage.This aspect of chronic-
phase CML bears an uncanny (and somewhat unsettling)
resemblance to human immunodeficiency virus, which mutates
rapidly to overcome antiviral agents. However, it is important
that Shah et al. found BCR-ABL mutations in some patients
before they received imatinib; this indicates that the develop-
ment of these mutations does not simply represent genetic
adaptation to selective pressure but is an intrinsic characteristic
of CML cells. In summary, the prevalence of mutant Bcr-Abl
kinases in relapsed CML likely results from multiple interacting
factors including the essential contribution of BCR-ABL to the
growth advantage of CML clones, some degree of genetic insta-
bility, a high rate of proliferation in the bone marrow, and the
strong selective pressure of imatinib in facilitating outgrowth of
mutant clones. As molecularly targeted small molecule
inhibitors are used to treat other cancers, it will be interesting to
ascertain if the paradigm of acquired resistance identified in
CML is broadly applicable. In particular, the widespread genom-
ic changes and occurrence of multiple oncogene and tumor
suppressor gene mutations in many epithelial cancers may
modulate their ability to become resistant to targeted agents.
What are the implications of these data for treating CML? A
particularly interesting aspect of the work of Shah et al. is the
study that chronic-phase patients had sustained hematologic
responses to imatinib but did not achieve major cytogenetic
responses. They found BCR-ABL mutations in four patients,
three of whom relapsed within 18 months. By contrast, a single
patient without a mutation relapsed over the same period (a
BCR-ABL gene amplification was identified). Besides reinforc-
ing the need for additional research to understand the mecha-
nisms of primary resistance in chronic-phase CML patients
without identifiable mutations, these preliminary data hint that
BCR-ABL mutational status may predict clinical outcome. If this
proves true in larger prospective trials, patients at high risk of
relapsing might be considered for combination therapies or, in
some instances, might be treated with higher doses of imatinib
to suppress mutations that confer an intermediate level of sensi-
tivity. To address this issue, it will be important to exploit
methodologies for identifying mutations in a minority of cells
that are more sensitive and less cumbersome than sequencing
multiple independent clones. Single-strand conformational poly-
morphism (SSCP) and denaturing high performance liquid
chromatography (DHPLC) analysis are robust screening
methodologies that can detect mutations in ?5% of a sample.
Reanalyzing the specimens included in the current study by
SSCP and/or DHPLC would be a simple way of comparing the
specificity and sensitivity of these strategies to the approach of
sequencing multiple independent clones. Regardless of how
samples are screened, prospective studies of the incidence and
impact of preexisting and acquired BCR-ABL mutations on the
responses of chronic-phase CML patients to imatinib should go
forward.
The presence of imatinib-resistant BCR-ABL mutations in a
high proportion of relapsed CML patients is an obvious concern
for clinicians, patients, and their families. However, many of the
patients reported by Shah et al. had advanced disease (blast
crisis) before treatment and may have therefore had both a
greater degree of genomic instability and more time to develop
resistant clones. While the actual incidence of imatinib-resistant
BCR-ABL species will need to be monitored closely in CML
patients who are treated early in the chronic phase, it may be
substantially lower. Indeed, Shah et al. found only four muta-
tions in their group of chronic-phase patients without cytogenet-
ic responses to imatinib.
Two historical precedents provide some additional perspec-
tive. In pediatric ALL, single-agent treatment with aminopterin or
corticosteroids induced transient remissions in many patients in
the 1950s and 1960s. It was not until these agents were
deployed in combination with vincristine, methotrexate, and
mercaptopurine that a substantial percentage of patients were
cured (reviewed in Pui, 1995). Progress has continued in pedi-
atric ALL with ?80% of children cured with modern regimens. A
more recent example is that of acute promyelocytic leukemia
(APL), which is associated with a t(15;17) that fuses the PML
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and RARA genes. Treatment with all trans retinoic acid induces
differentiation of the leukemic clone but is not curative. However,
when this agent is administered with moderate doses of con-
ventional chemotherapeutic agents, ?90% of patients can be
cured (reviewed in Warrell, 1996).With respect to CML and ima-
tinib, it is extraordinary that a majority of patients with a lethal
hematologic malignancy enter cytogenetic remission following
treatment with an oral agent that is well tolerated. However, the
experience in pediatric ALL, APL, and other cancers suggest
that combining drugs with distinct mechanisms of action may be
required to achieve high rates of cure. Administering imatinib
with cytotoxic agents such as cytosine arabinoside or with small
molecules that target hyperactive Ras (reviewed in Le and
Shannon, 2002) might be synergistic in CML and in BCR-ABL-
positive ALL. The recent progress in CML research has been
remarkable, and the work of Shah et al. raises a new set of bio-
logic and clinical questions. Most of all, these data remind us that
cancer is a tough and resilient adversary that can become resis-
tant to new therapeutics through genetic mechanisms that result
in highly specific modifications of relevant biochemical targets.
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